| Literature DB >> 28454439 |
Lu Sun1,2, Tianhua Liu1,2, Shu Zhang1, Kun Guo1, Yinkun Liu1,2.
Abstract
Octamer 4 (Oct4), a member of the Pit-Oct-Unc transcription factor family required to maintain self-renewal and pluripotency of embryonic stem cells, has been previously identified to be associated with tumorigenesis and malignant transformation of numerous types of cancer including hepatocellular carcinoma (HCC). The present data shows that Oct4 enhances cancer stem cell properties and increases invasion ability in the Huh7 cell line. To increase understanding of the role of Oct4 in HCC, the present study used a functional genomics approach and analyzed the resulting transcriptional profiles to identify Oct4-dependent genes in Huh7. Affymetrix GeneChip Human genome U133 Plus 2.0 Arrays were used to determine differential gene expression profiles and then validated by quantitative polymerase chain reaction. The present study found that altered expression of 673 genes (fold-change ≥2) affected multiple signaling pathways linked with self-renew and metastasis. Among these differentially expressed genes, the present study noticed that the key component of the WNT signaling pathway lymphoid enhancer binding factor 1 (LEF1) and Twist Family BHLH transcription factor 1 were upregulated by Oct4, whilst cadherin 2 was downregulated. Additional studies found that the nuclear β-catenin aggregation was increased in Oct4 overexpressed HCC cell lines. These results suggest that Oct4 regulates LEF1 to active LEF1/β-catenin dependent WNT signaling pathway and promote epithelial-mesenchymal transition. The present findings provide novel mechanistic insight into an important role of Oct4 in HCC.Entities:
Keywords: WNT signaling pathway; epithelial-mesenchymal transition; hepatocellular carcinoma; octamer 4
Year: 2017 PMID: 28454439 PMCID: PMC5403449 DOI: 10.3892/ol.2017.5788
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Primer sequences of genes used in the validation study.
| Gene | Primer sequence (5′-3′) |
|---|---|
| WNT2b | F: CCTTGTCTACTTTGACAACT |
| R: GAACCTGCAGCCTTGTCCAA | |
| FZD4 | F: TACCTCACAAAACCCCCATCC |
| R: GGCTGTATAAGCCAGCATCAT | |
| FZD8 | F: CTACGTGGGCAACCAGAGCC |
| R: CGGATGCGGAAGAGGGACA | |
| LEF1 | F: GACGAGATGATCCCCTTCAA |
| R: CGGGATGATTTCAGACTCGT | |
| CCND3 | F: TTTCCTGGCCTTCATTCTG |
| R: ATCATGGATGGCGGGTAC | |
| CTBP2 | F: CCACCTCATCAATGACTTTACC |
| R: AAGGCTTTCTCGTCCACC | |
| TGFB2 | F: ATCCCGCCCACTTTCTAC |
| R: CCGTTGTTCAGGCACTCT | |
| ACVR1C | F: ACCTGCTATTGCTCATCG |
| R: ACAGCCAACCCTAAGTCC | |
| LTBP1 | F: ATTCCACATACTCCCACC |
| R: TACCCACAGTTCCACAGC | |
| THBS1 | F: AGGGACGATGACTATGCTG |
| R: AGGACTGGGTGACTTGCT | |
| JAG1 | F: CTACTGCGACTGTCTTCCC |
| R: ACAGATACAGCGATAACCATT | |
| GAS1 | F: ACTGCGGCAAAGTCTTCAACGG |
| R: TGGGCATAGCCAGCATGTCCTC | |
| GAPDH | F: TCAAGAAGGTGGTGAAGCAG |
| R: GAGGGGAGATTCAGTGTGGT |
F, forward; R, reverse.
Figure 1.Oct4 expression enhances CSC property and invasion ability of HCC cell. (A) Oct4 enhances the abilities of sphere formation. (B) Oct4 enhances the abilities of soft agar colonization. (C) Oct4 enhances the abilities of Matrigel invasion. Graphs show the mean ± standard error of the mean from at least 3 experiments compared with mock cells. *P<0.05 was considered to indicate a statistically significant difference. Oct4, octamer 4; CSC, cancer stem cell; HCC, hepatocellular carcinoma; GFP, green fluorescent protein.
Figure 2.Heat map of differential expression genes. (A) Heat map visualization of 673 significantly regulated probe sets. The columns represent samples, whilst rows represent genes. Color key indicates gene expression value: Green, lowest and red, highest. (B) A series of pathways components were differentially expressed.
Distribution of differentially expressed genes in multiple signaling pathways by KEGG analysis.
| Pathway ID | Pathway name | Category | DEGs | P-value |
|---|---|---|---|---|
| hsa04010 | Mitogen activated protein kinase signaling pathway | Signal transduction | IL1R2, MEF2D, TGFB2, RPS6KA5, IL1R1, PLA2G12B, IL1RAP, ETS1, DOCK1, DUSP6, SOS2, KRAS, RPS6KA5, PLA2G12B, RAP1A | |
| hsa04350 | Transforming growth factor-β signaling pathway | Signal transduction | SOS2, TGFB2, KRAS, HNF4A, ACVR1C, INHBB | 0.002 |
| hsa04310 | Wnt signaling pathway | Signal transduction | SOX4, WNT2B, FZD8, CDH1, FZD4, SOX6, TGFB2, TLE3, TLE4, LEF1, SOX9, DKK1, ACVR1C, POU5F1, SOX5 | 0.0079 |
| hsa04630 | Jak-STAT signaling pathway | Signal transduction | SOCS1, SOS2, KRAS | 0.009 |
| hsa04330 | Notch signaling pathway | Signal transduction | JAG1, HEY1 | 0.1551 |
| hsa04340 | Hedgehog signaling pathway | Signal transduction | GAS1 | 0.2011 |
| hsa04060 | Cytokine-cytokine receptor interaction | Signaling molecules and interaction | CCL2, CXCL, SOCS1, IRS2, KRAS | |
| hsa04530 | Tight junction | Cell communication | CLDN11, MYL6, JAM3, CLDN1, PVRL3, CEBPA, TGFB2, CLDN14 | 0.0157 |
| hsa05200 | Pathways in cancer | Cancers | AKR1C1/AKR1C2, ALB, ANXA1, CD109, CD82, CDH1, CYP2C18, CD109, DKK1, E2F1, FGA, FGF2, FGL1, FOXQ1, GABRE, GJB1, GPC3, HPSE, HPX, IL8, IQGAP2, KNG1, KRAS, LEF1, LIF, MAG | |
| hsa04062 | Chemokine signaling pathway | Immune system | CCL2, CXCL12, GNAI1, KRAS | |
| hsa04610 | Complement and coagulation cascades | Immune system | SERPING1, CD55, C3, CFI, C8B, C5, C8A, C8G | |
| hsa04670 | Leukocyte transendothelial migration | Immune system | CLDN11, MYL6, JAM3, CLDN1, MMP16, VAV3, CXCL12, GNAI1, CLDN14, RAP1A, TIMP2 | 0.0005 |
| hsa05322 | Systemic lupus erythematosus | Immune disorders | KNG1, CREM, SOS2, C8B, KRAS, C5, C8A, C8G | 0.0189 |
| hsa03320 | PPAR signaling pathway | Endocrine system | IL1R2, NR2F1, NR0B2, SOS2, KRAS, IL1R1, IL1RAP | |
| hsa00010 | Glycolysis/gluconeogenesis | Carbohydrate Metabolism | ALDOB | 0.0027 |
| hsa00330 | Arginine and proline metabolism | Amino acid Metabolism | ASS1, ARG2, ARG1 | 0.0016 |
Figure 3.Validation of the gene expression profile of microarrays by reverse transcription-quantitative polymerase chain reaction. The results indicate that the DEG expression profile were mostly consistent with the microarray data analysis. The human GAPDH gene was selected as assay endogenous control for data normalization. Each gene expression level was calculated by a log equation (2−∆∆Cq). LEF1, wnt2B, FZD4, FZD8, CCND3, CTBP2, JAG1, GAS1, TGFβ2, ACVR1C, LTBP1 and THBS1 were upregulated following Oct4 overexpression. Graphs show mean ± standard error of the mean performed in triplicate. Oct4, octamer 4; GFP, green fluorescent protein; LEF1, lymphoid enhancer binding factor 1.
Figure 4.Oct4 activates LEF1/β-catenin dependent WNT signaling pathway and induces EMT. (A) Western blot analysis of EMT marker and LEF1. LEF1 and N-cadherin was upregulated in Oct4 overexpression cell lines, and E-cadherin expression was inhibited. (B) Immunofluorescence analysis of β-catenin shows that nuclear accumulation was promoted in Oct4 overexpression cell lines. Oct4, octamer 4; LEF1, lymphoid enhancer binding factor 1; EMT, epithelial-mesenchymal transition; GFP, green fluorescent protein.